Ambrx Biopharma (AMAM) signed a definitive agreement with Johnson & Johnson (JNJ) . Per the agreement terms, the pharma giant will acquire all outstanding shares of Ambrx for $28 per share in cash, aggregating to$2.0 billion. A clinical-stage biopharmaceutical company, Ambrx is focused on developing next-generation antibody drug conjugates (ADCs) designed to target multiple cancer indications. Its lead asset, ARX517, targets the prostate- specific membrane antigen (PSMA) expressed in prostate cancer cells. ...